The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab

BACKGROUND AND AIMS: The IMbrave 150 trial revealed the usefulness of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (HCC), making it now considered the first‐line systemic chemotherapy agent for HCC. The present study investigated factors associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Yasuto, Nouso, Kazuhiro, Fujioka, Shin‐ichi, Kariyama, Kazuya, Kobashi, Haruhiko, Uematsu, Shuji, Moriya, Akio, Hagihara, Hiroaki, Takabatake, Hiroyuki, Nakamura, Shinichiro, Yabushita, Kazuhisa, Kikuchi, Tatsuya, Oyama, Atsushi, Adachi, Takuya, Wada, Nozomu, Onishi, Hideki, Shiraha, Hidenori, Takaki, Akinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523973/
https://www.ncbi.nlm.nih.gov/pubmed/37537956
http://dx.doi.org/10.1002/cam4.6369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523973/
https://www.ncbi.nlm.nih.gov/pubmed/37537956
http://dx.doi.org/10.1002/cam4.6369

Ejemplares similares